|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | |
| A61K 39/395 | |||
| A61P 35/02 |
| (11) | Patento numeris | 3066129 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14803293.1 |
| Europos patento paraiškos padavimo data | 2014-11-06 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-09-14 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-06-19 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/064320 |
| Data | 2014-11-06 |
| (87) | Numeris | WO 2015/069874 |
| Data | 2015-05-14 |
| (30) | Numeris | Data | Šalis |
| 201361900898 P | 2013-11-06 | US |
| (72) |
GHOBRIAL, Irene M., US
ROCCARO, Aldo M., US
CARDARELLI, Josephine M., US
SACCO, Antonio, US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
Dana-Farber Cancer Institute, Inc., 450 Brookline Avenue, Boston, MA 02215, US |
| (54) | TREATMENT OF C1013G/CXCR4-ASSOCIATED WALDENSTRÖM`S MACROGLOBULINEMIA WITH AN ANTI-CXCR4 ANTIBODY |
| TREATMENT OF C1013G/CXCR4-ASSOCIATED WALDENSTRÖM`S MACROGLOBULINEMIA WITH AN ANTI-CXCR4 ANTIBODY |